Laboratory Medicine ›› 2025, Vol. 40 ›› Issue (6): 576-582.DOI: 10.3969/j.issn.1673-8640.2025.06.011
Previous Articles Next Articles
QU Li, CAO Hualin, ZHANG Rui, YANG Xike, YIN Xin
Received:
2024-05-16
Revised:
2025-02-07
Online:
2025-06-30
Published:
2025-07-01
CLC Number:
QU Li, CAO Hualin, ZHANG Rui, YANG Xike, YIN Xin. Roles of serum miR-524-5p and miR-708-5p expression levels in prognostic assessment of laryngeal cancer[J]. Laboratory Medicine, 2025, 40(6): 576-582.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2025.06.011
基因名称 | 正向引物(5'~3') | 反向引物(5'~3') |
---|---|---|
miR-524-5p | CTACAAAGGGAAGCACTTTTC | GTGCAGGGTCCGAGGT |
miR-708-5p | GGCGCGAAGGAGCTTACAATCTA | ATCCAGTGCAGGGTCCGAGG |
U6 | CTCGCTTCGGCAGCACA | AACGCTTCACGAATTTGCGT |
基因名称 | 正向引物(5'~3') | 反向引物(5'~3') |
---|---|---|
miR-524-5p | CTACAAAGGGAAGCACTTTTC | GTGCAGGGTCCGAGGT |
miR-708-5p | GGCGCGAAGGAGCTTACAATCTA | ATCCAGTGCAGGGTCCGAGG |
U6 | CTCGCTTCGGCAGCACA | AACGCTTCACGAATTTGCGT |
组别 | 例数 | miR-524-5p | miR-708-5p |
---|---|---|---|
喉癌组 | 93 | 0.51±0.12 | 0.49±0.11 |
正常对照组 | 93 | 1.12±0.18 | 1.09±0.14 |
t值 | 27.192 | 32.498 | |
P值 | <0.001 | <0.001 |
组别 | 例数 | miR-524-5p | miR-708-5p |
---|---|---|---|
喉癌组 | 93 | 0.51±0.12 | 0.49±0.11 |
正常对照组 | 93 | 1.12±0.18 | 1.09±0.14 |
t值 | 27.192 | 32.498 | |
P值 | <0.001 | <0.001 |
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
miR-524-5p | 0.801(0.736~0.865) | 0.788 | 74.19 | 77.42 | 0.516 |
miR-708-5p | 0.753(0.683~0.823) | 0.813 | 81.72 | 62.37 | 0.441 |
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
miR-524-5p | 0.801(0.736~0.865) | 0.788 | 74.19 | 77.42 | 0.516 |
miR-708-5p | 0.753(0.683~0.823) | 0.813 | 81.72 | 62.37 | 0.441 |
病理特征 | 例数 | miR-524-5p | miR-708-5p | 病理特征 | 例数 | miR-524-5p | miR-708-5p |
---|---|---|---|---|---|---|---|
性别 | TNM分期 | ||||||
男 | 52 | 0.52±0.13 | 0.51±0.15 | Ⅰ~Ⅱ期 | 51 | 0.55±0.13 | 0.53±0.12 |
女 | 41 | 0.50±0.11 | 0.47±0.08 | Ⅲ~Ⅳ期 | 42 | 0.46±0.10 | 0.44±0.09 |
t值 | 0.787 | 1.542 | t值 | 3.678 | 4.017 | ||
P值 | 0.433 | 0.127 | P值 | <0.001 | <0.001 | ||
年龄 | 肿瘤浸润深度 | ||||||
≥60岁 | 57 | 0.53±0.14 | 0.49±0.12 | T1~T2 | 61 | 0.52±0.13 | 0.50±0.12 |
<60岁 | 36 | 0.49±0.10 | 0.50±0.09 | T3~T4 | 32 | 0.50±0.09 | 0.47±0.08 |
t值 | 1.490 | 0.429 | t值 | 0.777 | 1.272 | ||
P值 | 0.140 | 0.669 | P值 | 0.439 | 0.207 | ||
淋巴转移 | 肿瘤分化程度 | ||||||
有 | 48 | 0.46±0.15 | 0.45±0.09 | 低分化 | 35 | 0.58±0.15 | 0.54±0.12 |
无 | 45 | 0.57±0.08 | 0.54±0.12 | 中高分化 | 58 | 0.47±0.08 | 0.46±0.10 |
t值 | 4.370 | 4.108 | t值 | 4.612 | 3.464 | ||
P值 | <0.001 | <0.001 | P值 | <0.001 | 0.001 | ||
肿瘤部位 | 病理类型 | ||||||
声门上型或声门型 | 60 | 0.52±0.13 | 0.50±0.12 | 鳞癌 | 90 | 0.51±0.12 | 0.49±0.11 |
声门下型 | 33 | 0.49±0.10 | 0.47±0.10 | 腺癌 | 3 | 0.47±0.11 | 0.52±0.13 |
t值 | 1.151 | 1.221 | t值 | 0.571 | 0.463 | ||
P值 | 0.253 | 0.225 | P值 | 0.569 | 0.645 | ||
肿瘤直径 | |||||||
≤3.0 cm | 43 | 0.53±0.14 | 0.52±0.13 | ||||
>3.0 cm | 50 | 0.47±0.09 | 0.47±0.09 | ||||
t值 | 2.491 | 2.180 | |||||
P值 | 0.015 | 0.032 |
病理特征 | 例数 | miR-524-5p | miR-708-5p | 病理特征 | 例数 | miR-524-5p | miR-708-5p |
---|---|---|---|---|---|---|---|
性别 | TNM分期 | ||||||
男 | 52 | 0.52±0.13 | 0.51±0.15 | Ⅰ~Ⅱ期 | 51 | 0.55±0.13 | 0.53±0.12 |
女 | 41 | 0.50±0.11 | 0.47±0.08 | Ⅲ~Ⅳ期 | 42 | 0.46±0.10 | 0.44±0.09 |
t值 | 0.787 | 1.542 | t值 | 3.678 | 4.017 | ||
P值 | 0.433 | 0.127 | P值 | <0.001 | <0.001 | ||
年龄 | 肿瘤浸润深度 | ||||||
≥60岁 | 57 | 0.53±0.14 | 0.49±0.12 | T1~T2 | 61 | 0.52±0.13 | 0.50±0.12 |
<60岁 | 36 | 0.49±0.10 | 0.50±0.09 | T3~T4 | 32 | 0.50±0.09 | 0.47±0.08 |
t值 | 1.490 | 0.429 | t值 | 0.777 | 1.272 | ||
P值 | 0.140 | 0.669 | P值 | 0.439 | 0.207 | ||
淋巴转移 | 肿瘤分化程度 | ||||||
有 | 48 | 0.46±0.15 | 0.45±0.09 | 低分化 | 35 | 0.58±0.15 | 0.54±0.12 |
无 | 45 | 0.57±0.08 | 0.54±0.12 | 中高分化 | 58 | 0.47±0.08 | 0.46±0.10 |
t值 | 4.370 | 4.108 | t值 | 4.612 | 3.464 | ||
P值 | <0.001 | <0.001 | P值 | <0.001 | 0.001 | ||
肿瘤部位 | 病理类型 | ||||||
声门上型或声门型 | 60 | 0.52±0.13 | 0.50±0.12 | 鳞癌 | 90 | 0.51±0.12 | 0.49±0.11 |
声门下型 | 33 | 0.49±0.10 | 0.47±0.10 | 腺癌 | 3 | 0.47±0.11 | 0.52±0.13 |
t值 | 1.151 | 1.221 | t值 | 0.571 | 0.463 | ||
P值 | 0.253 | 0.225 | P值 | 0.569 | 0.645 | ||
肿瘤直径 | |||||||
≤3.0 cm | 43 | 0.53±0.14 | 0.52±0.13 | ||||
>3.0 cm | 50 | 0.47±0.09 | 0.47±0.09 | ||||
t值 | 2.491 | 2.180 | |||||
P值 | 0.015 | 0.032 |
因素 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
HR①值(95%CI) | P值 | HR值(95%CI) | P值 | ||
淋巴转移 | 2.072(1.233~3.483) | 0.006 | 2.426(1.308~4.498) | 0.005 | |
肿瘤直径 | 2.468(1.613~3.776) | <0.001 | 2.124(1.110~4.064) | 0.023 | |
TNM分期 | 2.455(1.421~4.242) | 0.001 | 2.658(1.395~5.065) | 0.003 | |
肿瘤分化程度 | 3.159(1.635~6.103) | <0.001 | 2.641(1.364~5.112) | 0.004 | |
miR-524-5p | 2.726(1.565~4.747) | <0.001 | 2.925(1.544~5.541) | 0.001 | |
miR-708-5p | 3.273(1.779~6.021) | <0.001 | 3.552(1.875~6.729) | <0.001 |
因素 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
HR①值(95%CI) | P值 | HR值(95%CI) | P值 | ||
淋巴转移 | 2.072(1.233~3.483) | 0.006 | 2.426(1.308~4.498) | 0.005 | |
肿瘤直径 | 2.468(1.613~3.776) | <0.001 | 2.124(1.110~4.064) | 0.023 | |
TNM分期 | 2.455(1.421~4.242) | 0.001 | 2.658(1.395~5.065) | 0.003 | |
肿瘤分化程度 | 3.159(1.635~6.103) | <0.001 | 2.641(1.364~5.112) | 0.004 | |
miR-524-5p | 2.726(1.565~4.747) | <0.001 | 2.925(1.544~5.541) | 0.001 | |
miR-708-5p | 3.273(1.779~6.021) | <0.001 | 3.552(1.875~6.729) | <0.001 |
[1] | 黄海涛, 耿旭, 尚艳秋, 等. 2005—2016年中国喉癌发病及死亡趋势分析[J]. 中国全科医学, 2022, 25(5):608-614. |
[2] | NOCINI R, MOLTENI G, MATTIUZZI C, et al. Updates on larynx cancer epidemiology[J]. Chin J Cancer Res, 2020, 32(1):18-25. |
[3] | SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. |
[4] | MAHDIAN-SHAKIB A, DOROSTKAR R, TAT M, et al. Differential role of microRNAs in prognosis,diagnosis,and therapy of ovarian cancer[J]. Biomed Pharmacother, 2016, 84:592-600. |
[5] | TIAN Q, LU Y, YAN B, et al. Integrative bioinformatics analysis reveals that miR-524-5p/MEF2C regulates bone metastasis in prostate cancer and breast cancer[J]. Comput Math Methods Med, 2022, 2022:5211329. |
[6] | ZHANG J, WANG P, CUI Y. Long noncoding RNA NEAT1 inhibits the acetylation of PTEN through the miR-524-5p /HDAC1 axis to promote the proliferation and invasion of laryngeal cancer cells[J]. Aging(Albany NY), 2021, 13(22):24850-24865. |
[7] | ASKARI N, PIROUZ M S, MAFIKANDI V, et al. The lncRNA UCA1 enhances pancreatic cancer EMT by regulating miR-708-5p and miR-135b-5p:a bioinformatics approach[J]. Iran J Public Health, 2024, 53(7):1659-1669. |
[8] | WU X, TAN Y, TANG X. Long noncoding RNA MALAT1 promotes laryngocarcinoma development by targeting miR-708-5p/BRD4 axis to regulate YAP1-mediated epithelial-mesenchymal transition[J]. Biomed Res Int, 2022, 2022:8093949. |
[9] | 左文娜, 朱虹, 金爱燕, 等. 沉默MMP-9对喉癌细胞侵袭、迁移及PI3K/Akt磷酸化水平的影响[J]. 疑难病杂志, 2021, 20(10):987-991+996. |
[10] |
JI Z, FANG Z, DONG X, et al. Potential ferroptosis-related diagnostic and prognostic biomarkers in laryngeal cancer[J]. Eur Arch Otorhinolaryngol, 2022, 279(11):5277-5288.
DOI PMID |
[11] | MACNEIL S D. Non-squamous laryngeal cancer[J]. Otolaryngol Clin North Am, 2023, 56(2):345-359. |
[12] | JIANG S, YAN J, CHEN X, et al. Ginsenoside Rh2 inhibits thyroid cancer cell migration and proliferation via activation of miR-524-5p[J]. Arch Med Sci, 2020, 18(1):164-170. |
[13] |
ZHEN W, QIU D, ZHIYONG C, et al. MicroRNA-524-5p functions as a tumor suppressor in a human pituitary tumor-derived cell line[J]. Horm Metab Res, 2017, 49(7):550-557.
DOI PMID |
[14] | LIU G H, LIU Y H, YANG Z, et al. MicroRNA-524-5p suppresses the growth and invasive abilities of gastric cancer cells[J]. Oncol Lett, 2016, 11(3):1926-1932. |
[15] | 李顺乐, 张迪, 常帅, 等. circPUM1通过调控miR-524-5p表达对结肠癌细胞恶性生物学行为的影响[J]. 胃肠病学和肝病学杂志, 2021, 30(4):382-390. |
[16] | 华国安, 王蓉, 黄笑欢, 等. 微RNA-524-5p通过靶向抑制SOX9基因表达增加胃癌细胞的顺铂敏感性[J]. 肿瘤, 2019, 39(8):606-615. |
[17] | LIN K T, YEH Y M, CHUANG C M, et al. Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B[J]. Nat Commun, 2015, 6:5917. |
[18] |
WU X, LIU T, FANG O, et al. MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer[J]. Oncotarget, 2016, 7(3):2417-2432.
DOI PMID |
[19] | 丰天宇, 朱中凯, 王豪, 等. microRNA-708-5p对骨肉瘤细胞凋亡与迁移的作用及机制[J]. 中国细胞生物学学报, 2019, 41(3):446-455. |
[20] | WANG H, XU T, WU L, et al. Molecular mechanisms of MCM3AP-AS1 targeted the regulation of miR-708-5p on cell proliferation and apoptosis in gastric cancer cells[J]. Eur Rev Med Pharmacol Sci, 2021, 25(20):6159. |
[21] |
YU Y, CHANG Z, HAN C, et al. Long non-coding RNA MINCR aggravates colon cancer via regulating miR-708-5p-mediated Wnt/β-catenin pathway[J]. Biomed Pharmacother, 2020, 129:110292.
DOI PMID |
[22] | 郑宏, 曾振华, 唐建生, 等. circ-RAD23B通过miR-708-5p/CPNE1轴调控膀胱癌细胞增殖、细胞周期、凋亡的机制[J]. 中国老年学杂志, 2022, 42(17):4314-4320. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||